Attached files

file filename
10-K - FORM 10-K - ENTEST BIOMEDICAL, INC.entb0129form10k.htm
EX-32.1 - EXHIBIT 32.1 - ENTEST BIOMEDICAL, INC.entb0129form10kex321.htm
EX-31.2 - EXHIBIT 31.2 - ENTEST BIOMEDICAL, INC.entb0129form10kex312.htm
EX-32.2 - EXHIBIT 32.2 - ENTEST BIOMEDICAL, INC.entb0129form10kex322.htm
EX-31.1 - EXHIBIT 31.1 - ENTEST BIOMEDICAL, INC.entb0129form10kex311.htm
EX-10.37 - EXHIBIT 10.37 - ENTEST BIOMEDICAL, INC.entb0129form10kex1037.htm
EXCEL - IDEA: XBRL DOCUMENT - ENTEST BIOMEDICAL, INC.Financial_Report.xls
XML - IDEA: XBRL DOCUMENT - ENTEST BIOMEDICAL, INC.R3.htm
XML - IDEA: XBRL DOCUMENT - ENTEST BIOMEDICAL, INC.R8.htm
XML - IDEA: XBRL DOCUMENT - ENTEST BIOMEDICAL, INC.R5.htm
XML - IDEA: XBRL DOCUMENT - ENTEST BIOMEDICAL, INC.R9.htm
XML - IDEA: XBRL DOCUMENT - ENTEST BIOMEDICAL, INC.R1.htm
XML - IDEA: XBRL DOCUMENT - ENTEST BIOMEDICAL, INC.R4.htm
XML - IDEA: XBRL DOCUMENT - ENTEST BIOMEDICAL, INC.R2.htm
XML - IDEA: XBRL DOCUMENT - ENTEST BIOMEDICAL, INC.R7.htm
XML - IDEA: XBRL DOCUMENT - ENTEST BIOMEDICAL, INC.R6.htm
XML - IDEA: XBRL DOCUMENT - ENTEST BIOMEDICAL, INC.R16.htm
XML - IDEA: XBRL DOCUMENT - ENTEST BIOMEDICAL, INC.R10.htm
XML - IDEA: XBRL DOCUMENT - ENTEST BIOMEDICAL, INC.R30.htm
XML - IDEA: XBRL DOCUMENT - ENTEST BIOMEDICAL, INC.R20.htm
XML - IDEA: XBRL DOCUMENT - ENTEST BIOMEDICAL, INC.R21.htm
XML - IDEA: XBRL DOCUMENT - ENTEST BIOMEDICAL, INC.R42.htm
XML - IDEA: XBRL DOCUMENT - ENTEST BIOMEDICAL, INC.R27.htm
XML - IDEA: XBRL DOCUMENT - ENTEST BIOMEDICAL, INC.R24.htm
XML - IDEA: XBRL DOCUMENT - ENTEST BIOMEDICAL, INC.R17.htm
XML - IDEA: XBRL DOCUMENT - ENTEST BIOMEDICAL, INC.R25.htm
XML - IDEA: XBRL DOCUMENT - ENTEST BIOMEDICAL, INC.R26.htm
XML - IDEA: XBRL DOCUMENT - ENTEST BIOMEDICAL, INC.R43.htm
XML - IDEA: XBRL DOCUMENT - ENTEST BIOMEDICAL, INC.R44.htm
XML - IDEA: XBRL DOCUMENT - ENTEST BIOMEDICAL, INC.R40.htm
XML - IDEA: XBRL DOCUMENT - ENTEST BIOMEDICAL, INC.R22.htm
XML - IDEA: XBRL DOCUMENT - ENTEST BIOMEDICAL, INC.R37.htm
XML - IDEA: XBRL DOCUMENT - ENTEST BIOMEDICAL, INC.R23.htm
XML - IDEA: XBRL DOCUMENT - ENTEST BIOMEDICAL, INC.R35.htm
XML - IDEA: XBRL DOCUMENT - ENTEST BIOMEDICAL, INC.R31.htm
XML - IDEA: XBRL DOCUMENT - ENTEST BIOMEDICAL, INC.R29.htm
XML - IDEA: XBRL DOCUMENT - ENTEST BIOMEDICAL, INC.R14.htm
XML - IDEA: XBRL DOCUMENT - ENTEST BIOMEDICAL, INC.R36.htm
XML - IDEA: XBRL DOCUMENT - ENTEST BIOMEDICAL, INC.R41.htm
XML - IDEA: XBRL DOCUMENT - ENTEST BIOMEDICAL, INC.R38.htm
XML - IDEA: XBRL DOCUMENT - ENTEST BIOMEDICAL, INC.R28.htm
XML - IDEA: XBRL DOCUMENT - ENTEST BIOMEDICAL, INC.R13.htm
XML - IDEA: XBRL DOCUMENT - ENTEST BIOMEDICAL, INC.R33.htm
XML - IDEA: XBRL DOCUMENT - ENTEST BIOMEDICAL, INC.R32.htm
XML - IDEA: XBRL DOCUMENT - ENTEST BIOMEDICAL, INC.R15.htm
XML - IDEA: XBRL DOCUMENT - ENTEST BIOMEDICAL, INC.R18.htm
XML - IDEA: XBRL DOCUMENT - ENTEST BIOMEDICAL, INC.R34.htm
XML - IDEA: XBRL DOCUMENT - ENTEST BIOMEDICAL, INC.R39.htm
XML - IDEA: XBRL DOCUMENT - ENTEST BIOMEDICAL, INC.R11.htm
EX-10.39 - EXHIBIT 10.39 - ENTEST BIOMEDICAL, INC.entb0129form10kex1039.htm
XML - IDEA: XBRL DOCUMENT - ENTEST BIOMEDICAL, INC.R12.htm
v2.4.0.6
STOCKHOLDERS EQUITY
12 Months Ended
Aug. 31, 2012
Equity [Abstract]  
STOCKHOLDERS EQUITY

NOTE 13. STOCKHOLDERS EQUITY

 

The stockholders' equity section of the Company contains the following classes of capital stock as of August 31, 2012:

 

Common Stock:

 

$0.001 par value, 1,000,000,000 shares authorized 222,791,778 shares issued and outstanding as of August 31, 2012.

 

Preferred Stock:

 

$0.001 par value 5,000,000 shares authorized of 100,000 shares authorized is authorized as Series AA Preferred Stock , $001 par value of which 5,000 shares are issued and outstanding  as of  February 29, 2012  and 4,400,000 is authorized as Series B Preferred Stock of which 3, 201,397  shares are issued and outstanding as of August 31, 2012.

 

Upon any liquidation, dissolution, or winding up of the Company, whether voluntary or involuntary (collectively, a “Liquidation”), before any distribution or payment shall be made to any of the holders of Common Stock or any other series of preferred stock, the holders of Series B Preferred Stock shall be entitled to receive out of the assets of the Company, whether such assets are capital, surplus or earnings, an amount equal to $0.10 per share of Series B Preferred Stock (the “Liquidation Amount”) plus all declared and unpaid dividends thereon, for each share of Series B Preferred Stock held by them.

 

If, upon any Liquidation, the assets of the Company shall be insufficient to pay the Liquidation Amount, together with declared and unpaid dividends thereon, in full to all holders of Series B Preferred Stock, then the entire net assets of the Company shall be distributed among the holders of the Series B Preferred Stock, ratably in proportion to the full amounts to which they would otherwise be respectively entitled and such distributions may be made in cash or in property taken at its fair value (as determined in good faith by the Board), or both, at the election of the Board..

 

Non Voting Convertible Preferred Stock having a $1.00 par value:

 

200,000 shares authorized of which 75, 000 shares are issued and outstanding as of August 31, 2102.

 

Non Voting Convertible Preferred Stock shall convert at the option of the holder into shares of the corporation’s common stock at a conversion price equal to seventy percent (70%) of the lowest Closing Price for the five (5) trading days immediately preceding written receipt by the corporation of the holder’s intent to convert.

 

“CLOSING PRICE" shall mean the closing bid price for the corporation’s common stock on the Principal Market on a Trading Day as reported by Bloomberg Finance L.P.

 

“PRINCIPAL MARKET" shall mean the principal trading exchange or market for the corporation’s common stock.

 

“TRADING DAY” shall mean a day on which the Principal Market shall be open for business.